בר שפות
דלג על בר שפות
משרד הבריאות
חיפוש
דלג על חיפוש

יחידת המחקר

הגדל
יחידת המחקר הוקמה במטרה להעמיק את הידע בהפרעות נפשיות, ביטוייהן הקליניים, פתו-פיזיולוגיה וגישות טיפוליות, ולעידוד פעילות מחקרית ע"י צוות רב מקצועי במרכז הרפואי. מטרה נוספת ליצירה והעמקת ידע, היא הרחבת קשרים מקצועיים עם מוסדות רפואיים ואקדמאים בארץ ובעולם.
ביה"ח מסונף לפקולטה לרפואה בטכניון, ויחידת המחקר מהווה בסיס למתן הוראה לסטודנטים לרפואה מהטכניון. התפתחות היחידה במהלך השנים, הביאה לכך שהיום לוקחים חלק נכבד בפעילותה רופאים של המרכז, ומתמחים כחלק מתוכנית ההתמחות בפסיכיאטריה, במסגרת מדעי יסוד, במהלכה מבצעים את עבודת מדעי היסוד במרכזנו.
עד כה בוצעו עבודות ע"י כ – 40 מתמחים. חלק ניכר מתוצאות עבודות אלה פורסם בעיתונות מקצועית בינלאומית.
רוב העבודות מתמקדות בחקר הפרעות נפשיות על היבטיהן השונים כגון: סכיזופרניה, הפרעות אפקטיביות, שיטיון (דמנציה), מחקרים בתחום פסיכו-פרמקולוגיה.
נעשים מחקרים המתמקדים בחקר של שילוב סכיזופרניה עם הפרעה כפייתית טורדנית, כך שהפרסומים הרבים בעיתונות בינלאומית, הביאו להכרה שמדובר במחלה מיוחדת המצריכה שיטות אבחון וטיפול מיוחדות. פיתוח שיטות האבחון והטיפול, מתבצע ביחידת המחקר במרכז הרפואי לבריאות הנפש מעלה הכרמל.
מינויים אקדמאיים:
פרופ' מיכאל פוירובסקי – פרופ' חבר בפקולטה לרפואה טכניון, חיפה.
פרופ' אנטולי קריינין - פרופ' משנה.
ד"ר יוסף ברגמן – מרצה קליני.
ד"ר ארטאשז פשניאן – מדריך קליני.
להלן פרסומי עבודות מהשנים האחרונות:
פרופ' מיכאל פוירובסקי וד"ר ארטאשז פשניאן

##: Poyurovsky M, Faragian S, Fuchs C, Pashinian A. Effect of the selectivenorepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study. Isr J Psychiatry Relat Sci. 2009;46(3):213-20.

##Faragian S, Pashinian A, Fuchs C, Poyurovsky M. Obsessive-compulsive symptomdimensions in schizophrenia patients with comorbid obsessive-compulsive disorder.Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1009-12

##Poyurovsky M, Faragian S, Pashinian A, Heidrach L, Fuchs C, Weizman R, Koran L. Clinical characteristics of schizotypal-related obsessive-compulsive disorder. Psychiatry Res. 2008 May 30;159(1-2):254-8. Epub 2008 Apr 18.

##Poyurovsky M, Faragian S, Kleinman-Balush V, Pashinian A, Kurs R, Fuchs C. Awareness of illness and insight into obsessive-compulsive symptoms inschizophrenia patients with obsessive-compulsive disorder. J Nerv Ment Dis 2007 Sep;195(9):765-8.

##Poyurovsky M, Faragian S, Pashinian A, Levi A, Viosburd A, Stryjer R, Weizman R, Fuchs C, Weizman A. Neurological soft signs in schizophrenia patients with obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 2007 Spring;19(2):145-50.

##Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I.Attenuating effect of reboxetine on appetite and weight gain I olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2007 Jun;192(3):441-8.

פרופ' מיכאל פוירובסקי

Book
Poyurovsky M. Schizo-Obsessive Disorder, Cambridge University Press. 2013, Cambridge.Book chapters

  1. Poyurovsky M. Obsessive-Compulsive Phenomena in Schizophrenia: Clinical Symptoms, Neurobiological Correlates and Treatment. In: Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment, Ed. Pittenger C. Oxford University Press, 2015 (In press)
  2. Poyurosky M. OCD with schizotypal personality disorder ("Schizotypal OCD") In: Obsessive Compulsive Symptoms in Schizophrenia. Eds: De Haan L, Schirmbeck F, Zink M, Springer, 2014
  3. Poyurovsky M. Obsessive-Compulsive Disorder in Schizophrenia: Clinical Characterization and Treatment. In: Clinical Obsessive-Compulsive Disorders in Adults and Children. Eds Robert Hudak, MD; and Darin Doughtery, MD. Cambridge University Press, 2009
  4. Poyurovsky M, Weizman A, Weizman R. Schizo-obsessive Disorder. In: Obsessive-compulsive Spectrum Disorders, Eds: Gross-Isserof R, Weizman A., Martin Dunitz, 2006.
  5. Stryjer R, Strous RD, Shiloh R, Poyurovsky M, Weizman A. "5HT2a antagonists for the management of neuroleptic induced acute akathisia". “Focus on Serotonin Uptake Inhibitor Research.” Nova Science Publishers, Inc., 2006.
 :(Journal articles (shortened list

  1. Bleich-Cohen M, Jamshy S, Sharon H, Weizman R, Intrator N, Poyurovsky M,Hendler T. Machine learning fMRI classifier delineates subgroups of schizophrenia patients. Schizophr Res. 2014 Dec;160(1-3):196-200. doi:10.1016/j.schres.2014.10.033. Epub 2014 Nov 11. PubMed PMID: 25464921.
  2. Bleich-Cohen M, Poyurovsky M, Hendler T, Weizman R, Sharon H. Does co-morbidobsessive-compulsive disorder modify the abnormal language processing inschizophrenia patients? An FMRI study. Front Hum Neurosci. 2014 Jul 29;8:560.doi: 10.3389/fnhum.2014.00560. eCollection 2014. PubMed PMID: 25120459; PubMedCentral PMCID: PMC4114205.
  3. Bergman J, Pashinian A, Weizman A, Poyurovsky M. The beneficial effect ofescitalopram on obsessive-compulsive-related musical hallucinations in elderlypatients with hearing impairment: a case series. Int Clin Psychopharmacol. 2014Sep;29(5):263-5. doi: 10.1097/YIC.0000000000000037. PubMed PMID: 24810250.
  4. Poyurovsky M, Bergman J, Pashinian A, Weizman A. Beneficial effect of low-dosemirtazapine in acute aripiprazole-induced akathisia. Int Clin Psychopharmacol.2014 Sep;29(5):296-8. doi: 10.1097/YIC.0000000000000035. PubMed PMID: 24667488.
  5. Amrami-Weizman A, Maayan R, Gil-Ad I, Pashinian A, Fuchs C, Kotler M,Poyurovsky M. The effect of reboxetine co-administration with olanzapine onmetabolic and endocrine profile in schizophrenia patients. Psychopharmacology(Berl). 2013 Nov;230(1):23-7. doi: 10.1007/s00213-013-3199-1. Epub 2013 Jul 5.PubMed PMID: 23828160.
  6. Bleich-Cohen M, Hendler T, Weizman R, Faragian S, Weizman A, Poyurovsky M.Working memory dysfunction in schizophrenia patients with obsessive-compulsivesymptoms: an fMRI study. Eur Psychiatry. 2014 Mar;29(3):160-6. doi:10.1016/j.eurpsy.2013.02.004. Epub 2013 Jun 10. PubMed PMID: 23764406.
  7. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Weizman R, Weizman A. Reducingantipsychotic-induced weight gain in schizophrenia: a double-blindplacebo-controlled study of reboxetine-betahistine combination.Psychopharmacology (Berl). 2013 Apr;226(3):615-22. doi:10.1007/s00213-012-2935-2. Epub 2012 Dec 13. PubMed PMID: 23239133.
  8. Admon R, Bleich-Cohen M, Weizmant R, Poyurovsky M, Faragian S, Hendler T.Functional and structural neural indices of risk aversion in obsessive-compulsivedisorder (OCD). Psychiatry Res. 2012 Aug-Sep;203(2-3):207-13. doi:10.1016/j.pscychresns.2012.02.002. Epub 2012 Sep 5. PubMed PMID: 22959813.
  9. Faragian S, Fuchs C, Pashinian A, Weizman R, Weizman A, Poyurovsky M.Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients withschizo-obsessive disorder. Psychiatry Res. 2012 May 15;197(1-2):19-22. doi:10.1016/j.psychres.2012.02.024. Epub 2012 Mar 20. PubMed PMID: 22436351.
  10. Kulisevsky J, Poyurovsky M. Adenosine A2A-receptor antagonism andpathophysiology of Parkinson's disease and drug-induced movement disorders. EurNeurol. 2012;67(1):4-11. doi: 10.1159/000331768. Epub 2011 Nov 30. Review. PubMedPMID: 22134373.
  11. Bleich-Cohen M, Sharon H, Weizman R, Poyurovsky M, Faragian S, Hendler T.Diminished language lateralization in schizophrenia corresponds to impairedinter-hemispheric functional connectivity. Schizophr Res. 2012Feb;134(2-3):131-6. doi: 10.1016/j.schres.2011.10.011. Epub 2011 Nov 23. PubMedPMID: 22115994.
  12. Poyurovsky M, Zohar J, Glick I, Koran LM, Weizman R, Tandon R, Weizman A.Obsessive-compulsive symptoms in schizophrenia: implications for futurepsychiatric classifications. Compr Psychiatry. 2012 Jul;53(5):480-3. doi:10.1016/j.comppsych.2011.08.009. Epub 2011 Oct 27. PubMed PMID: 22036006.
  13. Salomon R, Bleich-Cohen M, Hahamy-Dubossarsky A, Dinstien I, Weizman R,Poyurovsky M, Kupchik M, Kotler M, Hendler T, Malach R. Global functionalconnectivity deficits in schizophrenia depend on behavioral state. JNeurosci.2011 Sep 7;31(36):12972-81. doi: 10.1523/JNEUROSCI.2987-11.2011. PubMed PMID:21900576.
  14. Bleich-Cohen M, Hendler T, Pashinian A, Faragian S, Poyurovsky M. Obsessivemusical hallucinations in a schizophrenia patient: psychopathological and FMRIcharacteristics. CNS Spectr. 2011 Jul;16(7):153-6. doi:10.1017/S1092852912000326. PubMed PMID: 24725500.
  15. Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M.Adherence to antipsychotic drug treatment in early-episode schizophrenia: asix-month naturalistic follow-up study. Schizophr Res. 2011 Aug;130(1-3):176-81.doi: 10.1016/j.schres.2011.04.030. Epub 2011 Jun 1. Erratum in: SchizophrRes.2013 May;146(1-3):379. PubMed PMID: 21636254.
  16. Poyurovsky M, Weizman R, Weizman A. Mirtazapine - a multifunctional drug: lowdose for akathisia. CNS Spectr. 2011 Feb;16(2):63. doi:10.1017/S1092852912000181. PubMed PMID: 22789775.
  17. Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Br JPsychiatry. 2010 Feb;196(2):89-91. doi: 10.1192/bjp.bp.109.070540. PubMed PMID:20118449.
  18. Poyurovsky M, Faragian S, Fuchs C, Pashinian A. Effect of the selectivenorepinephrine reuptake inhibitor reboxetine on cognitive dysfunction inschizophrenia patients: an add-on, double-blind placebo-controlled study. Isr JPsychiatry Relat Sci. 2009;46(3):213-20. PubMed PMID: 20039523.
  19. Faragian S, Pashinian A, Fuchs C, Poyurovsky M. Obsessive-compulsive symptomdimensions in schizophrenia patients with comorbid obsessive-compulsive disorder.Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 31;33(6):1009-12. doi:10.1016/j.pnpbp.2009.05.008. Epub 2009 May 15. PubMed PMID: 19447155.
  20. Poyurovsky M, Glick I, Koran LM. Lamotrigine augmentation in schizophreniaand schizoaffective patients with obsessive-compulsive symptoms. JPsychopharmacol. 2010 Jun;24(6):861-6. doi: 10.1177/0269881108099215. Epub 2008Dec 12. PubMed PMID: 19074541.
  21. Glick ID, Poyurovsky M, Ivanova O, Koran LM. Aripiprazole in schizophreniapatients with comorbid obsessive-compulsive symptoms: an open-label study of 15patients. J Clin Psychiatry. 2008 Dec;69(12):1856-9. Epub 2008 Nov 18. PubMedPMID: 19026264.
  22. Poyurovsky M, Faragian S, Shabeta A, Kosov A. Comparison of clinicalcharacteristics, co-morbidity and pharmacotherapy in adolescent schizophreniapatients with and without obsessive-compulsive disorder. Psychiatry Res. 2008 May30;159(1-2):133-9. doi: 10.1016/j.psychres.2007.06.010. Epub 2008 Apr 11. PubMedPMID: 18406469.
  23. Poyurovsky M, Faragian S, Pashinian A, Heidrach L, Fuchs C, Weizman R, KoranL. Clinical characteristics of schizotypal-related obsessive-compulsive disorder.Psychiatry Res. 2008 May 30;159(1-2):254-8. doi: 10.1016/j.psychres.2007.02.019.Epub 2008 Apr 18. PubMed PMID: 18378321.
  24. Poyurovsky M, Weizman R, Weizman A. Aripiprazole's receptor pharmacology andextrapyramidal side effects. Am J Psychiatry. 2008 Mar;165(3):398; author reply398-9. doi: 10.1176/appi.ajp.2007.07091513. PubMed PMID: 18316435.
  25. Poyurovsky M. Clozapine in treatment-refractory obsessive-compulsive disorderwith comorbid schizotypal personality disorder. Isr J Psychiatry Relat Sci.2008;45(3):219-20. PubMed PMID: 19398826.
  26. Poyurovsky M, Faragian S, Kleinman-Balush V, Pashinian A, Kurs R, Fuchs C.Awareness of illness and insight into obsessive-compulsive symptoms inschizophrenia patients with obsessive-compulsive disorder. J Nerv Ment Dis. 2007Sep;195(9):765-8. PubMed PMID: 17984777.
  27. Faragian S, Kurs R, Poyurovsky M. Insight into obsessive-compulsive symptomsand awareness of illness in adolescent schizophrenia patients with and withoutOCD. Child Psychiatry Hum Dev. 2008 Mar;39(1):39-48. Epub 2007 Jun 13. PubMedPMID: 17564828.
  28. Poyurovsky M, Faragian S, Pashinian A, Levi A, Viosburd A, Stryjer R, WeizmanR, Fuchs C, Weizman A. Neurological soft signs in schizophrenia patients withobsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 2007Spring;19(2):145-50. PubMed PMID: 17431060.
  29. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I.Attenuating effect of reboxetine on appetite and weight gain inolanzapine-treated schizophrenia patients: a double-blind placebo-controlledstudy. Psychopharmacology (Berl). 2007 Jun;192(3):441-8. Epub 2007 Feb 20. PubMedPMID: 17310385.
  30. Poyurovsky M, Fuchs C, Faragian S, Kriss V, Weisman G, Pashinian A, WeizmanR, Weizman A. Preferential aggregation of obsessive-compulsive spectrum disordersin schizophrenia patients with obsessive-compulsive disorder. Can J Psychiatry.2006 Oct;51(12):746-54. PubMed PMID: 17168249.
  31. Pashinian A, Faragian S, Levi A, Yeghiyan M, Gasparyan K, Weizman R, WeizmanA, Fuchs C, Poyurovsky M. Obsessive-compulsive disorder in bipolar disorderpatients with first manic episode. J Affect Disord. 2006 Aug;94(1-3):151-6. Epub2006 Jun 6. PubMed PMID: 16753221.
  32. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dosemirtazapine: a new option in the treatment of antipsychotic-induced akathisia. Arandomized, double-blind, placebo- and propranolol-controlled trial. BiolPsychiatry. 2006 Jun 1;59(11):1071-7. Epub 2006 Feb 21. PubMed PMID: 16497273.
  33. Poyurovsky M, Weizman R, Weizman A, Koran L. Memantine fortreatment-resistant OCD. Am J Psychiatry. 2005 Nov;162(11):2191-2. PubMed PMID:16263867.
  34. Poyurovsky M, Michaelovsky E, Frisch A, Knoll G, Amir I, Finkel B, Buniak F,Hermesh H, Weizman R. COMT Val158Met polymorphism in schizophrenia withobsessive-compulsive disorder: a case-control study. Neurosci Lett. 2005 Nov25;389(1):21-4. PubMed PMID: 16043283.
  35. Poyurovsky M, Bergman J, Weizman R. Obsessive-compulsive disorder in elderlyschizophrenia patients. J Psychiatr Res. 2006 Apr;40(3):189-91. PubMed PMID:15913654.
  36. Poyurovsky M, Koran LM. Obsessive-compulsive disorder (OCD) with schizotypyvs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. JPsychiatr Res. 2005 Jul;39(4):399-408. Epub 2004 Nov 13. Review. PubMed PMID:15804390.
  37. Koren D, Poyurovsky M, Seidman LJ, Goldsmith M, Wenger S, Klein EM. Theneuropsychological basis of competence to consent in first-episode schizophrenia:a pilot metacognitive study. Biol Psychiatry. 2005 Mar 15;57(6):609-16. PubMedPMID: 15780847.

Other publications:
Weizman A, Poyurovsky M, Tal V. Schizophrenia. Prologue Publishers, Rosh Ha’ayin, 1999.
Weizman A, Poyurovsky M, Tal V. Bipolar disorder. Prologue Publishers, Rosh Ha’ayin, 1999.


פרופ' אנטולי קריינין

  1. Poyurovsky M., Kreinin A., Modai I., Weizman A. Lithium-induced akathisia responds to low-dose mianserin. International Clinical Psychopharmacology 1995; 10: 261-263.
  2. Frisch A, Postilnick D, Rockah R, Michaelovsky E, Postilnick S, Birman E, Laor N, Rauchverger B, Kreinin A, Poyurovsky M, Schneidman M, Modai I, Weizman R. Association of unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. Molecular Psychiatry 1999; 4(4): 389-392.
  3. Kreinin A.,Epshtein S., Sheinkman A., Tel E. Sulpiride Augmentation for the Treatment of Clozapine-Induced Hypersalivation, Israel Journal of Psychiatry, 2005; 42 (1): 61-63.
  4. Kreinin A,Novizky D., Weizman A. Amisulpride in the Treatment of Hypersalivation Induced by Clozapine in Schizophrenia Patients. A Double--Blind, Crossover, Placebo-Controlled Study. International Clinical Psychopharmacology, 2006; 21:99–103.
  5. Kreinin A, Miodownik C, Libov I, Slavoutsky I, Lerner V. Moclobemide Treatment of Clozapine-induced Hypersalivation: Pilot Open Study. Clinical Neuropharmacology 2009; 32(3):151-153.
  6. Bergman J., Kreinin A. Vitamin C in Psychiatry. Past, Present and Future In: Lerner V., Miodownik, C. (eds). Food Supplements –A New Hope for Schizophrenia and Mood Disorders. Nova Science Publishers, Inc. 2009
  7. Feder Y, Nesher E, Ogran A, Kreinin A, Malatynska E, Yadid G, Pinhasov A. Selective breeding for dominant and submissive behavior in Sabra mice. Journal of Affective Disorders 2010; 126(1-2):214-222.
  8. Kreinin A, Miodownik C, Sokolik S, Shestakova D, Libov I, Bergman J, Lerner V. Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation. World Journal of Biological Psychiatry. 2011; 12(8):620-626.
  9. Pinhasov A, Nesher E, Gross M, Turgeman G, Kreinin A,Yadid G. The role of the PACAP signaling system in depression. Current Pharmaceutical Design, 2011; 17(10):990-1001.
  10. Kreinin A, Novitski D, Rabinowitz D, Weizman A, Grinshpoon A. Association between tobacco smoking and bipolar affective disorder: Clinical, epidemiological, cross-sectional, retrospective study in outpatients. Comprehensive Psychiatry 2012; 53(3):269–274. (In 2012, this article was the most cited article in the Bipolar Mood Disorder section of BioMedLib ) (http://wipimd.com/sttflpg=9eb4da777ef13bada4ed33e539deb8969b1ddb4813a3bde1)
  11. Kreinin A,Bawakny N, Ritsner M. Pregnenolone Augmentation in Recent-Onset Schizophrenia and Schizoaffective Disorders: An 8-week, Randomized, Double-Blind, Placebo-Controlled, 2-Center Trial. Israel Journal of Psychiatry, 2012; 49 (1): 35-36.
  12. Grinshpoon A, Goichman Y, Belgorodsky B, Gur O, Zafrir S, Atad Z, Melamed E, Lev Ami S, Hirshman S, Kreinin A. Computerized patients files in psychiatric hospitals. Logistics in Health Care, 2012 –Vol. 9, (1): 8213.Kreinin A, Krishtul V, Kirsh Z, Menuchin M,
  13. Kreinin I. Clinico-epidemiological comparison of delusion prominent and hallucination prominent clinical subgroups of paranoid schizophrenia. Clinical Schizophrenia & Related Psychoses. 2013 March 21:0-19 [Epub ahead of print]
  14. Bergman J, Miodownik C, Bersudsky Y, Sokolik S, Lerner P. P, Kreinin A., Poliakiwicz J, Lerner V. Curcumin as an add-on to antidepressive treatment: A randomized, double-blind, placebo-controlled, pilot clinical study. Clinical Neuropharmacology. 36(3):73-77, May/June 2013.
  15. Kreinin A., “Hearing voices”in schizophrenia: who’s voices are they? Medical Hypotheses 2013; 80: 352–356.
  16. Kreinin A, Bawakny N, Ritsner M. S. Adjunctive pregnenolone ameliorates the cognitive deficits in recentonset schizophrenia: An 8-week, randomized, double-blind, placebo controlled trial. Clinical Schizophrenia & Related Psychoses. 2014 Feb 4:1-31. [Epub ahead of print]
  17. Kreinin A, Shakera T, Sheinkman A, Levi T, Tal V, Polakiewicz J. Evacuation of a Mental Health Center During a Forest Fire in Israel. Disaster Med Public Health Prep. 2014 Jul 3:1-5.
  18. Kreinin A, Shakera T, Sheinkman A, Levi T, Tal V, Polakiewicz J. Evacuation of a mental health center during a forest fire in Israel. Disaster Med Public Health Prep. 2014 Aug;8(4):288-92. doi: 10.1017/dmp.2014.53. Epub 2014 Jul 3.
  19. Miodownik C, Bergman J, Lerner PP, Kreinin A, Lerner V. Amisulpride as Add-on Treatment for Resistant Obsessive-Compulsive Disorder:Retrospective Case Series. Clin Neuropharmacol. 2015 Jan-Feb; 38(1):26-9. doi: 10.1097/WNF.0000000000000065.
  20. Kreinin A, Lisson S, Nesher E, Schneider J, Bergman J, Farhat K, Farah J, Lejbkowicz F, Yadid G, Raskin L, Koman I, Pinhasov A.
Blood BDNF level is gender specific in severe depression. PLoS One. 2015 May 26;10(5):e0127643. doi: 10.1371/journal.pone.0127643. eCollection 2015.


ד"ר יוסף ברגמן

Poyurovsky M., Bergman J., Weizman R. Obsessive-compulsive disorder in elderly schizophrenic patients. Journal of Psychiatric Research, 40:189-191, 2006· Bergman J., Dwolatzky T., Brettholz I., Lerner V. Benefical Effect of Donepezil in the Treatment of Elderly Patients with Tardive Movement Journal of Clinical Psychiatry. 66:1, 107-110, 2006· Miodownik C., Lerner V., Bergman J., Dwolatzky T. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clinical Neuropharmacology, 29:68-72, 2006

עבור לתוכן העמוד